Labcorp Holdings Inc. Revenue & Financials

Labcorp's adjusted operating income of $1.797 billion in FY2024 produced a 13.8% adjusted operating margin, up from 13.2% in FY2023 — a margin expansion delivered despite persistent Medicare reimbursement rate reductions under the Protecting Access to Medicare Act. That expansion was achieved through the LaunchPad cost savings program and a mix shift toward specialty testing categories that carry higher margins than routine clinical chemistry. Reported revenue of $13.01 billion in FY2024 expanded to an estimated $13.95 billion in FY2025, reflecting continued health system partnership growth and a recovering pharmaceutical R&D spending environment in the Biopharma segment. The $7.90 billion backlog in Biopharma Laboratory Services as of early 2025 — with approximately $2.46 billion converting to near-term revenue — provides a degree of predictability that distinguishes the Covance-derived operations from the insurance-reimbursement volatility of the Diagnostics segment. The 13 health system and regional laboratory transactions closed or signed in 2025, including Baystate Health and Providence partnerships, represent a revenue growth strategy that carries lower capital intensity than building competing laboratories. Converting health system labs into Labcorp-managed operations locks in multi-year volume commitments while eliminating duplicate infrastructure costs on both sides. The market capitalization of $21.4 billion against $13.01 billion in revenue implies a price-to-sales ratio of approximately 1.6x — a valuation that prices the company as a services business with moderate growth prospects rather than a data or technology business. The 75 million patient dataset is the asset that most likely justifies a higher multiple if Labcorp can demonstrate revenue from that data beyond the testing transactions that generated it.